CCC Grand Rounds - 2014 Summer Semester

The Comprehensive Cancer Center (CCC) at the Medical University Vienna and the General Hospital Vienna continues its succsessfull lecture series during 2014 summer semester. Four top-class speakers will talk about the latest developements in the field of oncology, present recent study results and give insights into their current research projects. The CCC Grand Round lectures address cancer researchers, oncologists and pharmacists working at the Medical University Vienna and other institutions. The participants can be assigned credits for advanced training diploma (DFP).
After the lectures the CCC cordially invites you for an informally exchange and little refreshments.

Venue:

all lectures except Prof. Rutgers´ talk will take place at
Medical University Vienna
Jugendstilhörsaal, Level 02/03
Spitalgasse 23, Rektoratsgebäude (Building 88)
1090 Vienna


Wednesday, 5. March 2014, 2 p.m.
From the immune contexture to the Immunoscore in the era of cancer immunotherapies

Jérôme Galon
is immunologist, Research Director first class at INSERM (National Institute of Health and Medical Research) and head of an INSERM laboratory (Integrative Cancer Immunology) at the Cordeliers Research Center in Paris, France. Works from his laboratory on comprehensive analysis of the tumor-microenvironment and bioinformatics demonstrated that the adaptive immune reaction within the tumor was a better predictor of survival than traditional staging based on cancer's size and spread. Galon defined the concept of cancer immune-contexture, developed the Immunoscore and is Principal Investigator of the Immunoscore worldwide consortium. In his lecture Jérôme Galon will talk about the Immunoscore, its definition and its relevance as providing an essential prognostic tool.



Wednesday, 2. April 2014, 2 p.m.,

Venue: Großer Rektoratssaal, Medical University
Spitalgasse 23, Rektoratsgebäude (Building 88), 1090 Vienna

The axilla in breast cancer: from key to the surgeon to a no - go - zone

Emiel Rutgers
is a Surgical Oncologist at the Netherlands Cancer Institute in Amsterdam, Netherlands, Head of the Department of Surgery and Chair of the Institutes Breast Cancer Working Group. Rutgers’ main fields of interest is breast cancer, with emphasis on prognostic and predictive factors (micro-array techniques), risk management and prevention, and optimalisation of surgical procedures including neo-adjuvant chemotherapy, sentinel node procedure and immediate breast reconstruction. Emiel Rutgers is the principal investigator of the EORTC-AMAROS Trial (in sentinel node biopsy in breast cancer) and the EORTC MINDACT Trial, which is studying the value the 70-gene micro-array Mammaprint test in node negative and positive breast cancer. His lecture will focus on paradigm changes in the surgical management of the axillary lymph nodes.


Wednesday, 7. May 2014, 2 p.m.
Soft Tissue Sarcoma: from doxorubicin to personalized therapy

Peter Reichardt
is haematologist, Assistant Professor, Head of the Department of Interdisciplinary Oncology at the HELIOS Klinikum Berlin-Buch in Berlin, Germany, and Director of the Sarcoma Center Berlin-Brandenburg. Reichardt has led and conducted multiple clinical trials in bone sarcomas, soft tissue sarcomas and gastrointestinal stromal tumours in the adjuvant, advanced, and refractory settings. Peter Reichardt is a co-author of the current European Society for Medical Oncology (ESMO) guidelines for the management of GIST, soft tissue and bone sarcomas and a member of the ESMO Sarcoma Faculty. He is Chairman of the Scientific Committee of the GIST and Sarcoma patients’ organization “Das Lebenshaus”. In his lecture he will talk about modern treatment concepts which are tailoured to the particular tumor type.



Wednesday, 18. June 2014, 2 p.m.
Advances in ovarian cancer therapy

Andreas du Bois
is gynecologist and Head of the Department of Gynecology and gynecological Oncology at the Kliniken-Essen-Mitte, Germany. Du Bois´clinical focuses are operative gynecology und above all diagnosis as well as operative and systemic therapy of tumor diseases of the female genital. The internationally renowned scientist is founder of the studygroup AGO and member of a variety of national and international scientific societies in some of which he is engaged in an executive position. Furthermore, du Bois´ scientific work was honoured by numerous prizes. In his CCC Grand Round lecture he will point out the advances in ovarian cancer therapy.